How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial

Area of Science:

• Pharmacogenomics
• Clinical Pharmacology
• Genomic Medicine

Background:

• Growing patient demand for personalized medicine driven by direct-to-consumer genetic testing.
• Increasing awareness of genetic variability influencing drug response.
• Need for improved integration of genomic data into clinical practice.

Purpose of the Study:

• To provide guidance on transitioning from single-gene to panel-based pharmacogenetic testing.
• To demonstrate the application of a preemptive panel-based approach in an adult oncology clinic.
• To facilitate the adoption of panel-based pharmacogenetics in diverse clinical settings.

Main Methods:

• Implementation of a custom-designed pharmacogenetic panel (GatorPGx) at UF Health.
• Focus on pharmacogenes relevant to supportive care medications in chemotherapy.
• Demonstration in an adult solid tumor oncology clinic setting.

Main Results:

• Successful implementation of single-gene pharmacogenetic tests.
• Launch of a comprehensive, preemptive panel-based pharmacogenetic testing approach.
• Demonstrated utility of the GatorPGx panel in optimizing medication selection.

Conclusions:

• Panel-based pharmacogenetic testing offers a scalable approach to precision medicine.
• The GatorPGx panel can enhance supportive care for oncology patients.
• Guidance provided is applicable to various clinical practice settings for broader adoption.